Aktien Frankfurt Ausblick: Dax vor Zinsentscheidung der EZB in Warteposition | FRANKFURT (dpa-AFX) - Am Tag der Zinsentscheidung der Europäischen Zentralbank (EZB) wird der Dax zunächst kaum verändert erwartet. Von seinem am Dienstag erreichten Rekordhoch bei 19.633 Zählern wieder... ► Artikel lesen |
Biotech Report: Evotec legen zu, Qiagen unter Druck | (shareribs.com) Frankfurt / New York 16.10.2024 - Biotech-Aktien bewegten sich im deutschen Handel überwiegend im Plus. Unter anderem legten Vita34 und Evotec zu. Auch an der Wall Street legte der Sektor... ► Artikel lesen |
DZ BANK stuft QIAGEN NV auf 'Kaufen' | FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat die Einstufung für Qiagen auf "Kaufen" mit einem fairen Wert von 50 Euro belassen. Der Labordienstleister und Diagnostikspezialist verfüge u?ber ein ausgezeichnetes... ► Artikel lesen |
Longboard Pharmaceuticals, Inc.: Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline |
The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental... ► Artikel lesen |
Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline | VALBY, Denmark & LA JOLLA, Calif.--(BUSINESS WIRE)--H. Lundbeck A/S (Lundbeck) and Longboard Pharmaceuticals, Inc (NASDAQ: LBPH) (Longboard) today announced an agreement for Lundbeck to acquire... ► Artikel lesen |
Longboard Pharmaceuticals, Inc.: Longboard Pharmaceuticals to Present Late-Breaking and Encore Data at the 15th European Epilepsy Congress | Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it... ► Artikel lesen |
Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen |
Dyne Therapeutics Appoints Kerr As CMO | WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN) announced on Tuesday that Doug Kerr will take on the role of chief medical officer, replacing Wildon Farwell.Susanna High, chief operating... ► Artikel lesen |
Dyne Therapeutics, Inc.: Dyne Therapeutics Announces New Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented Dystrophin Expression and Functional Improvement in Multiple Cohorts | - Initiating Registrational Cohorts with Update on Path to Registration by Year-End 2024 -- Virtual Investor Event Today at 8:00 a.m. ET - WALTHAM, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics... ► Artikel lesen |